The hemagglutinating virus of Japan envelope (HVJ-E) vector derived from inactivated replication-defective Sendai virus enhances anti-
tumor immunity through activation of effector T cells and natural killer (NK) cells and inhibition of regulatory T cells (Tregs).
Interleukin (IL)-2 enhances T cell proliferation and activates T cells and NK cells. However, recent studies have revealed that the application of
IL-2 also has immune suppressive effects through expansion of Tregs. Here, we investigated the efficacy of
IL-2 gene therapy using immunomodulating HVJ-E vector in murine
malignant glioma models. A single intratumoral injection of HVJ-E containing pVAX-mIL-2 significantly suppressed
tumor growth of intracranial
gliomas, resulting in prolonged survival. Furthermore, HVJ-E, following intracavitary administration, delivered genes into post-operative
residual tumor cells. Consequently, prolonged survival resulted from a single intracavitary administration of HVJ-E containing pVAX-mIL-2 following
tumor removal.
IL-2 gene therapy delivered via the HVJ-E vector significantly inhibited the expansion of Tregs in
tumors compared to
IL-2 gene transfer using retroviral vector and resulted in marked infiltration of CD4(+) and CD8(+) T cells into
tumors. Through inhibition of Treg-mediated immunosuppression, HVJ-E enhanced effector T cell-mediated anti-
tumor immunity induced by
IL-2. This combination of an immunomodulating vector and immunostimulating
cytokine gene shows promise as an attractive, novel immunogene
therapy for
malignant glioma.